Literature DB >> 7371705

Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses.

M I Ramzan, E J Triggs, C A Shanks.   

Abstract

Plasma concentrations of gallamine were determined in 6 patients undergoing anaesthesia for elective surgery receiving a single intravenous bolus dose of 2 mg/kg and in a further 11 patients requiring additional doses (0.5 to 2 mg/kg) of the relaxant. The two-compartment open model was found to characterize adequately both the single and multiple dose data. No significant differences were noted when the model-independent pharmacokinetic parameters between the two groups of patients were compared with the exception of the distribution phase half-life (t1/2 alpha) (6.70 min single vs 9.19 min multiple p less than 0.05). Mean values for the pooled data for the half-life (t1/2 beta), plasma clearance (Clp) and volume of distribution (Vd beta) were 134.58 min, 1.20 ml/min/kg and 225.28 ml/kg respectively. Evoked twitch response was monitored in each patient to assess the degree of neuromuscular blockade. In only one patient was the bolus dose sufficient to produce complete (100%) blockade, thus the degree of maximal response varied between 78 to 100% and took some 3 to 10 minutes after dose administration. The concurrently measured gallamine plasma concentrations ranged from 9.30 to 19.20 micrograms/ml. Linear regression of the offset data (20 to 80% paralysis) in 10 patients revealed a recovery rate of 0.35 to 1.33%/min. For 5 patients where offset data was available over the entire range of response (0 to 100%) the calculated mean effective plasma concentrations for gallamine at 50 and 95% paralysis (ECp50, ECp95) were found to vary between 3.43 to 10.28 micrograms/ml, and 5.66 to 23.37 micrograms/ml respectively.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7371705     DOI: 10.1007/bf00562622

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Comparative clinical pharmacokinetics of tubocurarine, gallamine, alcuronium and pancuronium.

Authors:  W Buzello; S Agoston
Journal:  Anaesthesist       Date:  1978-07       Impact factor: 1.041

2.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

3.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

4.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

5.  Kinetics of distribution of radioactive labelled muscle relaxants. IV. Urinary elimination of a single dose of 14 C-gallamine.

Authors:  G Dal Santo
Journal:  Br J Anaesth       Date:  1972-04       Impact factor: 9.166

6.  Durations of action of d-tubocurarine and gallamine.

Authors:  L F Walts; J B Dillon
Journal:  Anesthesiology       Date:  1968 May-Jun       Impact factor: 7.892

7.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

8.  A preliminary investigation of the renal and hepatic excretion of gallamine triethiodide in man.

Authors:  S Agoston; G A Vermeer; U W Kersten; A H Scaf
Journal:  Br J Anaesth       Date:  1978-04       Impact factor: 9.166

9.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

10.  Pharmacokinetic studies in man with gallamine triethiodide. II. Single 4 and 6 mg/kg i.v. doses.

Authors:  M I Ramzan; E J Triggs; C A Shanks
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

View more
  7 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of the non-depolarising muscle relaxants.

Authors:  M I Ramzan; A A Somogyi; J S Walker; C A Shanks; E J Triggs
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

Review 3.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

4.  Pharmacokinetic studies in man with gallamine triethiodide. II. Single 4 and 6 mg/kg i.v. doses.

Authors:  M I Ramzan; E J Triggs; C A Shanks
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

5.  Analytical model of some pharmacokinetic and pharmacodynamic properties of fazadinium in man.

Authors:  A A d'Hollander; C Delcroix; P Duvaldestin; D Henzel; E Coussaert; J M Desmonts
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Clinical pharmacokinetics of alcuronium chloride in man.

Authors:  J Walker; C A Shanks; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

7.  Gallamine disposition in surgical patients with chronic renal failure.

Authors:  M I Ramzan; C A Shanks; E J Triggs
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.